Regenerative Medicine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Biologically Derived Materials, Genetically Engineered Materials, Synthetic Materials, Pharmaceuticals, Others), By Technology (Gene Therapy, Small Molecules and Biologicals, Cell Therapy, Tissue Engineering), By Application (Dermatology, Cardiovascular, Orthopaedic, Oncology, Wound Healing, Neurology, Ophthalmology, Others), By End-user (Hospitals, Clinics, Research Laboratories, Others) and Region Forecast 2020-2031

Regenerative Medicine Market size was valued at US$ 42.5 billion in 2024 and is expected to reach US$ 303.1 billion by 2031, growing at a significant CAGR of 32.4% from 2025-2031. Regenerative medicines are those, that replace, repair, and regenerate organ and tissues affected due to disease, injury, and the natural aging process. Regenerative medicines have a wide range of applications and are used in neurodegenerative, cardiovascular, orthopedic, and dermatological disorders. Regenerative medicines also include the possibility of growing organs and tissues in the laboratory and implanting them when the body cannot heal itself.

The major biomedical approaches in regenerative medicine are stem cells which have the ability of differentiation and proliferation of cells. An increase in the prevalence of genetic disorders, a rise in funding from public and private sectors for R&D activities in regenerative medicines, an increase in healthcare expenditure, and various products in the pipeline are expected to fuel the regenerative medicines market over the forecast period. Furthermore, technological advancements in stem cell therapy and nanotechnology, the growing need for orthopedic surgeries, and an increase in awareness about regenerative medicines among key stakeholders might propel the market growth over the forecast period.  

Key Developments

• In Oct 2023, Editas Medicine Inc., a clinical-stage genome editing business, announced that EDIT-301, an experimental gene editing medication, has been designated as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for the treatment of severe sickle cell disease (SCD).
• In May 2024, Andelyn Biosciences, Inc., a premier and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), partnered with the California Institute for Regenerative Medicine's (CIRM), to produce adeno-associated vectors (AAV) therapies using its suspension AAV CuratorTM Platform.